[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

← Portfolio

SMN2 Splicing Enhancer (Oral)

Edit / manage →

Spinal muscular atrophy

Phase 1Clinical entrySmall moleculeNeuromuscularMixed· high conf3 evidence-linked claims3 snapshots

Overview

Disease area
Neuromuscular
Indication
Spinal muscular atrophyMONDO:0009670
Mechanism of action
SMN2 pre-mRNA splicing modifier increasing full-length SMN
Development stage
Phase 1
Institution
Lakeshore Neuroscience Institute
Principal investigators
R. Halvorsen
Targets
SMN1SMN2
Pathways
SMN protein restoration
Trial registry
NCT01754441

Intake & funding

Applications
  • R. HalvorsenfundedUSD1,200,0002023-06-01
    Translational grant
Funding events
  • milestone_paymentUSD500,000Series A2024-10-15
  • awardUSD1,200,000Demo Translational Institute2023-09-01

Timeline

state through time · newest first
  1. Q4 2024Series B planning
    Milestones
    • ·Phase 2 protocol finalized
    Accomplishments
    • ·Regulatory alignment on motor-function endpoints
    Challenges
    • ·Site activation slower than planned
    Next steps
    • ·First patient in Phase 2
    • ·Expand manufacturing
    Risk themes:Enrollment competition with approved therapies
  2. Q3 2024Series A fully funded
    Milestones
    • ·Phase 1 MAD initiated
    Accomplishments
    • ·PD biomarker reproduced across sites
    Challenges
    • ·Differentiation vs risdiplam requires head-to-head convenience data
    Next steps
    • ·Design Phase 2 in treatment-naive infants
    Risk themes:Differentiation thesis unproven
  3. Q2 2024Series A fully funded
    Milestones
    • ·Phase 1 SAD completed
    Accomplishments
    • ·Dose-dependent SMN protein increase in blood
    • ·No dose-limiting toxicities
    Challenges
    • ·CNS exposure margin narrower than modeled
    Next steps
    • ·Initiate MAD cohort
    • ·Confirm CSF pharmacodynamics
    Risk themes:CNS exposureCrowded SMA market

Scientific assessment

1 claims
  • Mechanistic RationaleStrong

    Oral SMN2 pre-mRNA splice modifier increases exon-7 inclusion to raise full-length SMN protein, a mechanism clinically validated by risdiplam.

    trialNCT01754441· 2023-09-10

Translational assessment

1 claims
  • BiomarkersModerate

    Blood SMN protein and SMN2 copy number serve as pharmacodynamic and stratification biomarkers.

    publicationPMID:28249145

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

1 claims
  • Standard of CareLimited

    Crowded SMA landscape (nusinersen, risdiplam, onasemnogene) requires a differentiation thesis on oral convenience and CNS exposure.

    internallandscape-2024

Execution assessment

0 claims

No evidence linked yet.

Structured reviews

1 reviews
Mixed· high confInternalIC review2024-11-20
Strengths

Clinically validated mechanism; clean early safety.

Weaknesses

Crowded SMA market; differentiation rests on convenience.

Improvement areas

Generate head-to-head convenience and CNS-exposure data.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Clinical entry
    Entered Phase 1 MAD; Phase 2 planned.2024-07-01

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.